The Metabolic Characteristics in Sublobar Areas of PRE Based on FDG-PET Study
The Metabolic Characteristics in Sublobar Areas of PRE Based on FDG-PET Study
Epilepsy is a chronic brain disease that is caused by various factors and characterized by
 recurrent, episodic and temporary central nervous system dysfunction. In the past few
 decades, despite the continuous development of antiepileptic drugs, there are still 20%-30%
 patients with epilepsy progressing to pharmacoresistant epilepsy (PRE), which leads to a
 significant increase in the morbidity and mortality of epilepsy. For those fraction of PRE,
 surgical treatment may be the only possible way to cure epilepsy. Accurate presurgical
 evaluation play an important role in making surgery decision and defining surgical extent and
 achieve better surgical outcome. Imaging, especially interictal
 fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) is widely used in
 preoperative evaluation, which is of great significance in the detection of epileptogenic
 foci. Previous studies on FDG-PET have found that FDG-PET has a wide range of hypometabolism
 inpatients of PRE varying from different epileptic origins. Therefore, exploring the
 characteristics of glucose metabolism originating in different brain areas of resistant
 epilepsy can help to better interpret the results of FDG-PET and guide the preoperative
 localization of such patiens and better understand the potential mechanism of seizure
 propagation in PRE.
Inclusion Criteria: (a) Pharmacoresistant Epilepsy may be defined by International League
 Against Epilepsy (ILAE）as failure of adequate trials of two tolerated and appropriately
 chosen and used AED schedules (whether as monotherapies or in combination) to achieve
 sustained seizure freedom (judged by two epileptologists); (b) conventional MRI negative or
 nonspecific abnormalities; and (c) detailed information of long-term video-EEG, FDG-PET,
 high resolution MRI (HR-MRI) and neuropsychological assessment were acquired, (d) focal
 epilepsy defined by combining clinical, electrophysical and neuroimaging.

 Exclusion Criteria: (a) generalized or multifocal epilepsy or the patient's electroclinical
 features were inconsistent with pharmacoresistant epilepsy; (b) idiopathic focal epilepsy;
 and (c) unsatisfactory imaging quality.

 -